Author(s): Made Krisna Adi Jaya, Putu Rika Veryanti, I Gusti Agung Ayu Kartika

Email(s): krisnaadijaya@unud.ac.id

DOI: 10.52711/0974-360X.2021.00815   

Address: Made Krisna Adi Jaya1*, Putu Rika Veryanti2, I Gusti Agung Ayu Kartika3
1Department of Pharmacy, Faculty of Math and Science, Udayana University, Bali, Indonesia.
2Department of Pharmacy, Faculty of Pharmacy, Institut Sains dan Teknologi Nasional, Jakarta, Indonesia.
3Pharmacology and Clinical Pharmacy Department, School of Pharmacy, Institut Teknologi Bandung, Indonesia.
*Corresponding Author

Published In:   Volume - 14,      Issue - 9,     Year - 2021


ABSTRACT:
Background: Bisoprolol is a beta-blocker agent that is widely used as an antihypertensive agent, cardiac rate control, and agent to improve the cardiac ejection fraction. Bisoprolol is commonly added to hypertension therapy in patients with a high risk of heart disease such as hypertension with diabetes. The effectiveness of beta-blocker agents in the treatment of hypertension in geriatrics with diabetes without a history of CVD who are currently using dual therapy is still minimal. Evaluation of this matter needs to be done to complement scientific evidence in the use of bisoprolol in the treatment of hypertension in geriatrics with type 2 diabetes mellitus. Objective: This study aims to compare the effectiveness of bisoprolol as additional therapy in geriatric patients who have diabetes hypertension without CVD history while they are ongoing dual oral antihypertension therapy. Method: A cohort study involving 82 geriatrics was prospectively observed for four weeks. The exposure in this study was the bisoprolol agent. Subjects were divided into two groups, where all patients would undergo dual antihypertensive agents, namely Angiotensin-Receptor-Blocker (ARB) and Calcium-Channel-Blocker (CCB). Reductions in systolic and diastolic blood pressure were observed as primary outcomes, and success in achieving blood pressure goals was observed as a secondary outcome in the study. Result: There was no difference in the decrease in systolic and diastolic blood pressure in the exposure and non-exposure groups (p> 0.05). Judging from the large number of patients who successfully achieved the therapeutic target also showed no significant difference between the exposure and non-exposure groups with systolic and diastolic risk difference (RD) values of 1,091 (CI95%: 0.545-2.184) and 1,222 (CI95%: 0.781-1.913). Conclusion: The addition of bisoprolol agents in geriatric patients with hypertension and diabetes without a history of CVD is not required.


Cite this article:
Made Krisna Adi Jaya, Putu Rika Veryanti, I Gusti Agung Ayu Kartika. Effectivity Evaluation of Bisoprolol as Additional Hypertension Therapy in Geriatrics with Type 2 Diabetes Mellitus while ongoing with Dual Oral Anti-Hypertension Agent: A Cohort Study. Research Journal of Pharmacy and Technology. 2021; 14(9):4691-6. doi: 10.52711/0974-360X.2021.00815

Cite(Electronic):
Made Krisna Adi Jaya, Putu Rika Veryanti, I Gusti Agung Ayu Kartika. Effectivity Evaluation of Bisoprolol as Additional Hypertension Therapy in Geriatrics with Type 2 Diabetes Mellitus while ongoing with Dual Oral Anti-Hypertension Agent: A Cohort Study. Research Journal of Pharmacy and Technology. 2021; 14(9):4691-6. doi: 10.52711/0974-360X.2021.00815   Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-9-29


REFERENCES:
1.    Chobanian A V., Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on: Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. USA: U.S. Department of Health and Human Services; 2003. 1–34.
2.    Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008; 26(2): 351–6.
3.    Paras V, Kinjal V. A Review on New Antihypertensive Agent: Irbesartan. Asian J Res Pharm Sci 2016; 6(1): 34-36.
4.    Vasudevan NJ. Flax Seeds-An Overview in Hypertension. Int J Adv Nurs Manag [Internet]. 2017; 5(3): 273-278.
5.    Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: Systematic review and metaanalysis. BMC Psychiatry. 2008; 8(1): 1-14.
6.    Messerli FH, Bangalore S, Julius S. Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension. Circulation. 2008; 117(20): 2706–2715.
7.    Beygi N, Dehghan M, Iranmanesh S. Treatment adherence and its determinant factors amongst outpatients with Hypertension: A Case of Iran. Int J Nurs Educ Res. 2017; 5(3): 287-292.
8.    Tripathi N, Balai MK. A Study to assess the Quality of life among Persons living with Hypertension, Diabetes Mellitus and Arthritis in selected Village of Ludhiana, Punjab. Int J Nurs Educ Res. 2018; 6(4): 379-382.
9.    Palanisamy S, Sumathy A, Sundaramoorthi C, Kumaran KA. Drug Use Evaluation of Antihypertensives at a Teaching Hospital in South India. Res J Pharm Tech. 2009; 2(3): 477–481.
10.    Sumathy P, Monika M. A Prospective Study on Comparative Efficacy between three Combinational Therapies for Hypertension. Res J Pharm Technol. 2017; 10(1): 273-276.
11.    Sumathy P, Shanmugasundaram P, Monika M. A prospective study on comparative efficacy between two combinational therapies for hypertension. Res J Pharm Technol. 2016; 9(11): 2005-2008.
12.    Antonakoudis G, Poulimenos L, Kifnidis K, Zouras C, Antonakoudis H. Blood pressure control and cardiovascular risk reduction. Hippokratia. 2007; 11(3): 114–119.
13.    B Meher, Satapathy T, Parida J, Maharana A. Comparative Study between ACE Inhibitors and ARB Inhypertensive Patients. Res J Pharmacol Pharmacodyn. 2012; 4(5): 263–266.
14.    D GB. The rationale of use of combination therapy in hypertensive patients. Res J Pharmacol Pharmacodyn. 2013; 5(1): 19–26.
15.    R PH. Antihypertensive Drugs prescribed in West Indian Territories. Res J Pharmacol Pharmacodyn. 2013; 5(1): 75–79.
16.    DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D’Ascenzo F, Cerrato E, et al. β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Hear. 2015; 2(1): 1–12.
17.    Jani B, Rajkumar C. Ageing and vascular ageing. Postgrad Med J. 2006 Jun 1;82(968):357–62.
18.    Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1(1): 1–93.
19.    Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical Practice Guidelines for the Management of Hypertension in the Community. J Clin Hypertens. 2014;16(1):14–26.
20.    Radchenko, Sirenko, Kushnir, Torbas, Dobrohod. Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. Vasc Health Risk Manag. 2013; 9(1): 535–549.
21.    Park S, Rhee M-Y, Lee SY, Park SW, Jeon D, Kim B-W, et al. A prospective, randomized, open-label, active-controlled, clinical trial to assess central haemodynamic effects of bisoprolol and atenolol in hypertensive patients. J Hypertens. 2013; 31(4): 813–819.
22.    Mahmud A, Feely J. -Blockers Reduce Aortic Stiffness in Hypertension but Nebivolol, Not Atenolol, Reduces Wave Reflection. Am J Hypertens. 2008; 21(6): 663–667.
23.    Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. Differential Effects of Nebivolol and Metoprolol on Central Aortic Pressure and Left Ventricular Wall Thickness. Hypertension. 2011; 57(6): 1122–1128.
24.    Pucci G, Ranalli MG, Battista F, Schillaci G. Effects of β-Blockers with and Without Vasodilating Properties on Central Blood Pressure. Hypertension. 2016; 67(2): 316–324.
25.    Eguchi K, Hoshide S, Kario K. Effects of Celiprolol and Bisoprolol on Blood Pressure, Vascular Stiffness, and Baroreflex Sensitivity. Am J Hypertens. 2015; 28(7): 858–867.
26.    Ram CVS. Beta-Blockers in Hypertension. Am J Cardiol. 2010; 106(12): 1819–1825.
27.    Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. Cardiovasc Diabetol. 2019; 18(1): 163.
28.    Messerli FH, Grossman E. Hypertension in Diabetes Mellitus. Drugs. 2001; 61(10): 1531–1533.
29.    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA. 2014; 311(5): 507-520.
30.    Viswanathan V, Ganesh J. Management of diabetic hypertensives. Indian J Endocrinol Metab. 2011; 15(4): 374–379.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available